SK862004A3 - Liquid formulation comprising cetuximab and a fatty acid ester of polyoxyethylene sorbitan - Google Patents

Liquid formulation comprising cetuximab and a fatty acid ester of polyoxyethylene sorbitan Download PDF

Info

Publication number
SK862004A3
SK862004A3 SK86-2004A SK862004A SK862004A3 SK 862004 A3 SK862004 A3 SK 862004A3 SK 862004 A SK862004 A SK 862004A SK 862004 A3 SK862004 A3 SK 862004A3
Authority
SK
Slovakia
Prior art keywords
cetuximab
solution
liquid pharmaceutical
pharmaceutical composition
polyoxyethylene
Prior art date
Application number
SK86-2004A
Other languages
English (en)
Slovak (sk)
Inventor
Hanns-Christian Mahler
Robert Muller
Ulrike Martini-Marr
Udo Haas
Christiane Bachmann
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of SK862004A3 publication Critical patent/SK862004A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
SK86-2004A 2001-07-13 2002-06-18 Liquid formulation comprising cetuximab and a fatty acid ester of polyoxyethylene sorbitan SK862004A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10133394A DE10133394A1 (de) 2001-07-13 2001-07-13 Flüssige Formulierung enthaltend Cetuximab
PCT/EP2002/006696 WO2003007988A1 (de) 2001-07-13 2002-06-18 Flüssige formulierung enthaltend cetuximab und einen polyoxyethylensorbitanfettsäureester

Publications (1)

Publication Number Publication Date
SK862004A3 true SK862004A3 (en) 2004-07-07

Family

ID=7691220

Family Applications (1)

Application Number Title Priority Date Filing Date
SK86-2004A SK862004A3 (en) 2001-07-13 2002-06-18 Liquid formulation comprising cetuximab and a fatty acid ester of polyoxyethylene sorbitan

Country Status (18)

Country Link
US (1) US20040170632A1 (ja)
EP (1) EP1406658A1 (ja)
JP (1) JP2004536129A (ja)
KR (1) KR20040018458A (ja)
CN (1) CN1231264C (ja)
AR (1) AR039358A1 (ja)
BR (1) BR0211060A (ja)
CA (1) CA2453342A1 (ja)
CZ (1) CZ2004189A3 (ja)
DE (1) DE10133394A1 (ja)
HU (1) HUP0401046A3 (ja)
MX (1) MXPA04000340A (ja)
PE (1) PE20030433A1 (ja)
PL (1) PL364599A1 (ja)
RU (1) RU2004102395A (ja)
SK (1) SK862004A3 (ja)
WO (1) WO2003007988A1 (ja)
ZA (1) ZA200401161B (ja)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004071439A2 (en) * 2003-02-10 2004-08-26 Elan Pharmaceuticals, Inc. Immunoglobulin formulation and method of preparation thereof
DE10355251A1 (de) * 2003-11-26 2005-06-23 Merck Patent Gmbh Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
DE10355904A1 (de) 2003-11-29 2005-06-30 Merck Patent Gmbh Feste Formen von anti-EGFR-Antikörpern
JP2007522157A (ja) * 2004-02-12 2007-08-09 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 抗ｅｇｆｒ抗体の高濃縮液体製剤
NZ550430A (en) * 2004-04-27 2009-06-26 Wellstat Biologics Corp Cancer treatment using viruses and camptothecins
JP2008519757A (ja) * 2004-11-12 2008-06-12 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 抗ｅｇｆｒ抗体の固形物
CN101163468A (zh) * 2005-02-28 2008-04-16 卫材R&D管理有限公司 磺酰胺化合物的新联合用途
JP5133071B2 (ja) 2006-02-09 2013-01-30 第一三共株式会社 抗癌医薬組成物
JP2009535372A (ja) 2006-05-03 2009-10-01 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 抗ｅｄｂフィブロネクチンドメイン抗体ｌ１９−ｓｉｐ及び抗−ｅｇｆｒ−抗体の組合せ
US20080112953A1 (en) * 2006-10-06 2008-05-15 Amgen Inc. Stable formulations
EP2094247B1 (en) * 2006-10-20 2022-06-29 Amgen Inc. Stable polypeptide formulations
CN107773755B (zh) * 2016-08-31 2021-06-22 上海津曼特生物科技有限公司 抗表皮生长因子受体单克隆抗体的注射液制剂
CA3063324A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
US11738068B2 (en) 2018-06-25 2023-08-29 Jcr Pharmaceuticals Co., Ltd. Protein-containing aqueous liquid formulation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) * 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5945098A (en) * 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
WO1996040210A1 (en) * 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
CA2226575C (en) * 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation

Also Published As

Publication number Publication date
CZ2004189A3 (cs) 2004-05-12
JP2004536129A (ja) 2004-12-02
DE10133394A1 (de) 2003-01-30
CA2453342A1 (en) 2003-01-30
CN1527724A (zh) 2004-09-08
HUP0401046A2 (en) 2006-04-28
MXPA04000340A (es) 2004-05-04
EP1406658A1 (de) 2004-04-14
ZA200401161B (en) 2004-10-22
WO2003007988A1 (de) 2003-01-30
CN1231264C (zh) 2005-12-14
RU2004102395A (ru) 2005-05-27
KR20040018458A (ko) 2004-03-03
PL364599A1 (en) 2004-12-13
US20040170632A1 (en) 2004-09-02
PE20030433A1 (es) 2003-05-24
HUP0401046A3 (en) 2006-11-28
BR0211060A (pt) 2004-07-20
AR039358A1 (es) 2005-02-16

Similar Documents

Publication Publication Date Title
US20230047111A1 (en) Pharmaceutical formulations of tnf-alpha antibodies
JP4317010B2 (ja) ＩｇＧ抗体の安定な凍結乾燥医薬製剤
TWI322693B (en) Pharmaceutical preparation comprising an antibody against the egf receptor
JP7473603B2 (ja) 液体医薬組成物
JP2005513110A (ja) Ｅｇｆ受容体に対する抗体を含む凍結乾燥製剤
CN103068367B (zh) 用于稳定含有蛋白质的制剂的含有烷基糖苷的组合物和方法
SK862004A3 (en) Liquid formulation comprising cetuximab and a fatty acid ester of polyoxyethylene sorbitan
US11712472B2 (en) Pharmaceutical composition comprising anti-human TSLP receptor antibody
CN114632150A (zh) 一种抗pd-l1人源化单克隆抗体的药物组合物
JP3714951B2 (ja) Ｉｌ−６含有薬剤組成物
JP6885875B2 (ja) 液体医薬組成物
CN112004522A (zh) 使用葡甲胺盐稳定包含蛋白的制剂的方法
BR112019012686A2 (pt) métodos e formulações para a redução do tempo de reconstituição de polipeptídeos liofilizados
CN114746439A (zh) 整合蛋白抗体的稳定制剂
WO2023233277A1 (en) Lyophilized pharmaceutical compositions of copper histidinate
OA17126A (en) Pharmaceutical formulations of TNF-alpha antibodies

Legal Events

Date Code Title Description
FC9A Refused patent application